# A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia

> **NCT07256912** · PHASE4 · NOT_YET_RECRUITING · sponsor: **International Agency for Research on Cancer** · enrollment: 1266 (estimated)

## Conditions studied

- Vaccine Effectiveness
- HPV Vaccination
- Single Dose
- Immunogenicity
- Cervical Cancer Prevention
- Quadrivalent HPV Vaccine

## Interventions

- **BIOLOGICAL:** quadrivalent HPV vaccine
- **BIOLOGICAL:** quadrivalent HPV vaccine

## Key facts

- **NCT ID:** NCT07256912
- **Lead sponsor:** International Agency for Research on Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2029-01-15
- **Target enrollment:** 1266 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07256912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07256912, "A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07256912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*